Prelude Therapeutics Inc

PRLD

Company Profile

  • Business description

    Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

  • Contact

    175 Innovation Boulevard
    WilmingtonDE19805
    USA

    T: +1 302 467-1280

    E: [email protected]

    https://www.preludetx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    131

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,434.5034.700.41%
CAC 407,626.8470.08-0.91%
DAX 4023,115.96133.69-0.58%
Dow JONES (US)41,113.97284.970.70%
FTSE 1008,559.3338.09-0.44%
HKSE22,941.91250.031.10%
NASDAQ17,738.1648.500.27%
Nikkei 22536,896.00116.340.32%
NZX 50 Index12,526.0629.170.23%
S&P 5005,631.2824.370.43%
S&P/ASX 2008,205.2026.900.33%
SSE Composite Index3,355.2612.600.38%

Market Movers